CA-ATTACKIQ
20.4.2022 15:02:05 CEST | Business Wire | Press release
AttackIQ ®, the leading independent vendor of Breach and Attack Simulation (BAS) systems, today announced a new integration with Vectra®, an AI-driven threat detection and response platform that enables joint customers to detect attacks that have bypassed existing security controls and ensure rapid response to the latest threats.
"In today's hyper-complex threat environment, organizations must think proactively and adopt advanced security capabilities to prevent successful attacks," said Carl Wright, Chief Commercial Officer at AttackIQ. "This integration will allow our customers to validate the efficacy of the Vectra AI platform by utilizing AttackIQ's PCAP replay and related network scenarios to find and fix coverage gaps throughout their security infrastructure before adversaries exploit them."
AttackIQ operates under the "assume breach" mindset, recognizing that it is not a question of if but when an intruder will break past an organization's perimeter defense. Leveraging automated breach and attack simulation technology and the MITRE ATT&CK framework, the AttackIQ Security Optimization Platform enables organizations to measure their security controls performance, identify misconfigurations or gaps in coverage, and focus resources on areas with the highest probability of risk exposure.
"It is exciting to see AttackIQ and Vectra joining forces to help customers enable a proactive, threat-informed defense," said Geert Busse, Head of Next-Gen Solutions Pre Sales EMEA, Westcon. "As key vendors in our Westcon Next Generation Solutions go-to-market strategy, these two organizations are the backbone of our technology pillar, focusing on defense against emerging threats by delivering automation, integration and efficiency that our industry needs to detect and stop the latest generation of Threat Actors."
The Vectra Platform uses security-led artificial intelligence (AI) to power threat detection and response to ensure speed, precision, and efficiency in surfacing and stopping attacks before devastating impact. The platform captures data from network packets and logs that give insight into companies' public cloud and SaaS environment, federated identity, and data center networks. Vectra's patented approach to applying AI to detection analyzes all detection to prioritize threats and map events to MITRE ATT&CK framework without noise and hunting. It further drives appropriate remediation and rapid response through other tools already implemented in your security stack.
The AttackIQ Security Optimization Platform integration with the Vectra Threat Detection and Response Platform is available today.
To learn more about this integration and see it in action register for the May 5th demo here: https://attackiq.com/get-a-demo/weekly-demo/ .
About AttackIQ
AttackIQ, the leading independent vendor of breach and attack simulation solutions, built the industry's first Security Optimization Platform for continuous security control validation and improving security program effectiveness and efficiency. AttackIQ is trusted by leading organizations worldwide to plan security improvements and verify that cyberdefenses work as expected, aligned with the MITRE ATT&CK framework. The Company is committed to giving back to the cybersecurity community through its free award-winning AttackIQ Academy , open Preactive Security Exchange, and partnership with MITRE Engenuity's Center for Threat-Informed Defense . For more information, visit www.attackiq.com . Follow AttackIQ on Twitter , Facebook , LinkedIn , and YouTube .
About Vectra AI
Vectra® is a leader in threat detection and response for hybrid and multi-cloud enterprises. The Vectra platform uses AI to detect threats at speed across public cloud, identity, SaaS applications, and data centers. Only Vectra optimizes AI to detect attacker methods—the TTPs at the heart of all attacks—rather than simplistically alerting on "different". The resulting high-fidelity threat signal and clear context enables security teams to respond to threats sooner and to stop attacks in progress faster. Organizations worldwide rely on Vectra for cybersecurity resilience in the face of dangerous cyber threats and to prevent ransomware, supply chain compromise, identity takeovers, and other cyberattacks from impacting their businesses. For more information, visit vectra.ai.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220420005006/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
